At Maha Pharma, we take our research and development responsibilities seriously. Since we opened our doors in 2002, our active research team has undertaken more than 35 clinical trials, enrolling nearly 4,000 patients. Most of these trials were done in the process of developing and testing various Maha Pharma products.
Investing in research is top priority for us. On average, Maha Pharma re-invests 13 per cent of sales to research in Europe annually.
As a member of Rx&D (European's Research Based Pharmaceutical Companies) we actively support the objective of discovering new medicines that improve the quality of health care for every European.
Exciting News: Save on Your First Order – Register Now for a 20% Discount!